Telehealth peptide prescriptions are legal in the U.S. when a clinician licensed in the patient’s state sets up a valid clinician-patient relationship and prescribes a drug that can lawfully be dispensed. The federal Ryan Haight Act limits online prescribing only for controlled substances, and DEA’s temporary flexibilities for those run through December 31, 2026.[1][2] Most peptides, including semaglutide and tirzepatide, are not controlled substances, so state rules and FDA drug law matter more.
This guide explains what each law covers. It does not rate or recommend any telehealth company. For related topics, see our FDA and regulation hub and the guide to 503A vs 503B compounding.
Which laws apply to telehealth prescribing?
| Layer | Who sets it | What it covers |
|---|---|---|
| Ryan Haight Act (21 U.S.C. 829(e)) | Congress; enforced by DEA | Online prescribing of controlled substances only[2] |
| DEA telemedicine flexibilities | DEA and HHS temporary rule | Waive the in-person visit for controlled substances through Dec 31, 2026[1] |
| Licensure and standard of care | State medical boards and legislatures | Who can practice on a patient in that state, and what a valid relationship requires |
| Drug approval, compounding, labeling | FDA (FD&C Act) | Whether the drug can be lawfully made, sold and promoted[9] |
| Advertising, pricing, reviews | FTC (FTC Act sections 5 and 12) | Deceptive or unfair marketing and billing[8] |
The Ryan Haight Act covers controlled substances only
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires at least one in-person medical evaluation before a practitioner prescribes a controlled substance over the internet, unless one of seven statutory telemedicine exceptions applies. Once that in-person evaluation has happened, the Act’s remote-prescribing limits no longer apply to that practitioner-patient relationship.[1][2]
The Act matters for a few drugs that come up around peptide and weight-loss care, such as testosterone (Schedule III) and phentermine (Schedule IV). It does not cover unscheduled drugs. Semaglutide, tirzepatide and nearly all peptides discussed on this site are not scheduled; see are peptides legal? for how the different legal categories fit together.
DEA telemedicine flexibilities through 2026
During the COVID-19 public health emergency, DEA used an exception in the Act to let practitioners prescribe controlled substances by telemedicine without first seeing the patient. DEA and HHS have extended those flexibilities four times. The fourth temporary rule, published December 31, 2025, runs from January 1 through December 31, 2026.[1]
Under it, a DEA-registered practitioner can prescribe Schedule II–V controlled medications by audio-video telemedicine without a prior in-person visit; audio-only is allowed for Schedule III–V narcotic medications for opioid use disorder. Prescriptions must still meet other DEA rules and applicable federal and state law.[1]
DEA proposed a permanent special registration for telemedicine in January 2025. The proposal would create registrations that let qualifying clinicians prescribe, and online platforms dispense, certain controlled substances by telemedicine without an in-person visit, plus state-level telemedicine registrations.[3] As of mid-October 2026, no final rule or fifth extension had been published in the Federal Register, so the rules for 2027 are not yet known.
What happens after December 31, 2026?
There are three realistic outcomes, and none has been announced:
- A final special registration rule takes effect, and clinicians who prescribe controlled substances remotely must register under it.
- A fifth temporary extension keeps the current flexibilities for another period, as DEA and HHS did in 2023, 2024 and 2025.[1]
- Neither happens, and the Ryan Haight Act’s default returns: a new patient would generally need an in-person evaluation before a practitioner could prescribe a controlled substance remotely.[2]
None of these outcomes changes the rules for non-controlled drugs such as GLP-1s. Check DEA’s site before relying on any date.
State licensure and a valid prescriber-patient relationship
States, not the federal government, license clinicians and define a valid clinician-patient relationship.
- Where the patient is: state boards generally treat care as happening where the patient is located, so the clinician needs a license in that state unless a state exception applies.
- Establishing the relationship: many states allow it by telehealth if the visit meets the same standard of care as an in-person visit. Some require video rather than a questionnaire alone for certain drugs.
- Prescribing standards: boards can discipline clinicians who prescribe without an adequate history, exam or follow-up, whatever the platform.
Because these rules vary, check your own state medical board. Our guide to state medical board peptide therapy rules covers board statements in more detail.
What the drug itself must be
A valid prescription does not make an unlawful product lawful. Compounded peptides must meet Section 503A or 503B conditions; for 503A, that includes a prescription for an identified individual patient.[9] Peptides sold as “research use only” are not meant for people at all. FDA has sent warning letters to telehealth companies marketing unapproved drugs such as retatrutide, and to sellers of GLP-1s labeled “for research purposes.”[7] See research-use-only peptides.
FDA and FTC actions on telehealth GLP-1 marketing
| Date | Agency | Action |
|---|---|---|
| Sept 9, 2025 | FDA | Launched a crackdown on deceptive drug advertising: thousands of letters and about 100 cease-and-desist letters[4] |
| Dec 2025 | FTC | Final order against telehealth company NextMed over allegedly misleading prices, fake reviews and unsupported weight-loss claims for GLP-1 programs; $150,000 for refunds[8] |
| Feb 6, 2026 | FDA | Said it would restrict GLP-1 ingredients used in mass-marketed compounded drugs and act on misleading claims[6] |
| Mar 3, 2026 | FDA | Warning letters to 30 telehealth companies over compounded GLP-1 marketing[5] |
FDA’s stated concerns are specific. Companies may not call compounded products generics or equivalents of approved drugs, claim they contain the same active ingredient, or claim they are clinically proven.[6] In March 2026, FDA also objected to telehealth firms selling compounded drugs under their own brand names in ways that implied the firm made the drug.[5]
The FTC case is a settlement, not a court finding of liability. It shows that pricing that leaves out drug, lab or visit costs can be treated as deceptive.[8] For more, see legal risks of buying peptides online and FDA warning letters on peptides.
Questions to ask before a telehealth visit
- Is the clinician licensed in my state, and can I see their name and license number?
- Will there be a real-time video visit, and who handles follow-up and side effects?
- Is the drug approved, or compounded? If compounded, which pharmacy makes it, and under 503A or 503B?
- Does the quoted price include the medication, labs and visits?
This is general information, not legal advice. Federal and state telehealth rules are changing, and the DEA deadline above is close.
